Sunho Biologics, Inc. (HKG:2898)

Market Cap	970.43M +56.7%
Revenue (ttm)	18.63K -99.9%
Net Income	-89.95M
EPS	-0.60
Shares Out	151.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	100
Open	n/a
Previous Close	6.39
Day's Range	n/a
52-Week Range	3.99 - 8.60
Beta	n/a
RSI	46.98
Earnings Date	Mar 27, 2026

About Sunho Biologics

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 128
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2898

Financial Performance

In 2024, Sunho Biologics's revenue was 38,000, a decrease of -99.78% compared to the previous year's 17.53 million. Losses were -79.97 million, -39.74% less than in 2023.

Financial numbers in CNY